Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:IMTXNASDAQ:LENZNASDAQ:OYST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$7.58+2.8%$8.65$3.51▼$14.44$647.12M0.821.22 million shs1.11 million shsIMTXImmatics$5.14+4.3%$4.51$3.30▼$13.77$624.77M0.87651,557 shs301,788 shsLENZLENZ Therapeutics$28.71-2.3%$25.56$14.42▼$38.93$808.07M0.41184,042 shs214,492 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-2.12%-2.12%-21.76%-8.67%+84.25%IMTXImmatics-3.52%-8.70%+9.07%+16.00%-57.86%LENZLENZ Therapeutics+4.37%+2.33%+9.42%+33.76%+87.26%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.9203 of 5 stars3.71.00.04.73.60.80.6IMTXImmatics2.0802 of 5 stars3.62.00.00.03.21.70.0LENZLENZ Therapeutics1.86 of 5 stars3.60.00.00.03.62.50.0OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00480.47% UpsideIMTXImmatics 3.20Buy$14.67185.34% UpsideLENZLENZ Therapeutics 3.17Buy$46.6062.31% UpsideOYSTOyster Point Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OYST, LENZ, AVXL, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.003/18/2025LENZLENZ TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AIMTXImmatics$144.15M4.33N/AN/A$2.88 per share1.78LENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/AOYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)IMTXImmatics-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%8/12/2025 (Estimated)LENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%8/13/2025 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/ALatest OYST, LENZ, AVXL, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45IMTXImmaticsN/A3.983.98LENZLENZ TherapeuticsN/A28.6328.63OYSTOyster Point Pharma8.493.353.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%IMTXImmatics64.41%LENZLENZ Therapeutics54.32%OYSTOyster Point Pharma96.70%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%IMTXImmatics3.30%LENZLENZ Therapeutics38.40%OYSTOyster Point Pharma17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/AOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionableOYST, LENZ, AVXL, and IMTX HeadlinesRecent News About These CompaniesAviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and InnovationApril 1, 2025 | finance.yahoo.comBillion-dollar real estate bet could spark a biotech revivalMarch 21, 2025 | bizjournals.comVibrant Wintertime Flower At Oyster Point: PhotoFebruary 20, 2025 | msn.comNext phase of Kilroy's big Oyster Point project sees interest beyond biotechFebruary 11, 2025 | bizjournals.comThe Oyster Point Gallery presents "The Cut-Outs" by Gary Steven GrovesJanuary 14, 2025 | newjerseystage.comTed Danson, Kristen Bell and D’Arcy Carden Reunite at “A Man on the Inside ”Premiere 4 Years After “The Good Place ”(Exclusive)November 12, 2024 | msn.comTransmucosal Drug Delivery Pipeline Report 2024 - Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesNovember 12, 2024 | finance.yahoo.comHow A.I. Is Disrupting Pharma: The High-Stakes Race to Revolutionize Drug DiscoveryNovember 12, 2024 | observer.comEyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNovember 7, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy RatingNovember 7, 2024 | markets.businessinsider.comIndian stocks rally over Trump's win; Sensex jumps 901 pointsNovember 6, 2024 | malaysiasun.comUS election: Treasuries slip on election day as volatility hits one-year highNovember 6, 2024 | moneycontrol.comDaily Voice: This fund manager is strategically accumulating positions in healthcare, consumer staples in recent market pullbackNovember 6, 2024 | moneycontrol.comUS Elections| Why outcome does not matter in the long-run; market strategist makes a $19-million pointNovember 5, 2024 | moneycontrol.comHow to Talk About Oysters Like You Know What You're Talking AboutOctober 31, 2024 | foodandwine.comEyePoint Pharma Prices Public Offering Of About 12.73 Mln Shares At $11.00/shrOctober 30, 2024 | markets.businessinsider.comScotiabank Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)October 29, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for DuravyuOctober 29, 2024 | marketwatch.comPositive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy RatingOctober 26, 2024 | markets.businessinsider.comPositive Outlook for EyePoint Pharmaceuticals Amid Promising Phase 3 Trials for DuravyuOctober 25, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOYST, LENZ, AVXL, and IMTX Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$7.58 +0.21 (+2.85%) Closing price 04:00 PM EasternExtended Trading$7.55 -0.03 (-0.40%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Immatics NASDAQ:IMTX$5.14 +0.21 (+4.26%) Closing price 04:00 PM EasternExtended Trading$5.15 +0.01 (+0.19%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.LENZ Therapeutics NASDAQ:LENZ$28.71 -0.69 (-2.35%) Closing price 04:00 PM EasternExtended Trading$28.66 -0.05 (-0.17%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Oyster Point Pharma NASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings ThredUp Stock Reverses on AI Buzz, Eyes Double-Digit Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
